Long term efficacy and safety of patients with Ankylosing spondylitis treated with etanercept for 5 years: Analysis of different types of response

被引：0
|
作者：
Baraliakos, Xenofon [1 ]
Listing, J. [2 ]
Fritz, C. [2 ]
Song, In-Ho [3 ]
Haibel, H. [3 ]
Heldmann, F. [1 ]
Rudwaleit, M. [3 ]
Sieper, J. [3 ]
Braun, Juergen [1 ]
机构：
[1] Rheumazentrum Ruhrgebiet, Herne, Germany
[2] German Rheumatism Res Ctr, Berlin, Germany
[3] Charite, Berlin, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S357 / S357
页数：1
相关论文
共 50 条
  • [31] Sustained long-term clinical efficacy and safety for up to 2.5 years of etanercept in patients with psoriasis
    Elewski, B
    Leonardi, C
    Gottlieb, A
    Strober, B
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB225 - AB225
  • [32] Sustained long-term clinical efficacy and safety in patients with psoriasis for up to 2.5 years on etanercept
    Serban, Anca
    Elewski, Boni
    Leonardi, Craig
    Gottlieb, Alice
    Strober, Bruce
    van der Kerkhof, Peter C. M.
    Ortonne, Jean Paul
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1813 - 1813
  • [33] Persistent clinical efficacy and safety of inlifiximab in patients with Ankylosing spondylitis over 7 years - Evidence for different response to anti-trif-a therapy
    Baraliakos, Xenofon
    Listing, J.
    Fritz, C.
    Alten, R.
    Burmester, G.
    Krause, A.
    Schewe, S.
    Schneider, M.
    Soerensen, H.
    Zeidler, H.
    Rudwaleit, M.
    Sieper, J.
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S583 - S583
  • [34] LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
    Burmester, G. R.
    Stigler, J.
    Rubbert-Roth, A.
    Tanaka, Y.
    Azevedo, V. F.
    Coombs, D.
    Mccaskill, R.
    Lippe, R.
    Wung, P.
    Gensler, L. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 607 - 608
  • [35] Persistent clinical efficacy and safety of infliximab in patients with ankylosing spondylitis over 7 years - Evidence for different response to anti-TNFA therapy
    Baraliakos, X.
    Listing, J.
    Burmester, G.
    Krause, A.
    Schewe, S.
    Schneider, M.
    Soerensen, H.
    Zeidler, H.
    Sieper, J.
    Braun, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (04) : 746 - 746
  • [36] Clinical Efficacy and Safety of Etanercept Versus Sulfasalazine in Patients With Ankylosing Spondylitis A Randomized, Double-Blind Trial
    Braun, Juergen
    van der Horst-Bruinsma, Irene E.
    Huang, Feng
    Burgos-Vargas, Ruben
    Vlahos, Bonnie
    Koenig, Andrew S.
    Freundlich, Bruce
    ARTHRITIS AND RHEUMATISM, 2011, 63 (06): : 1543 - 1551
  • [37] Clinical response to long-term therapy with infliximab in patients with ankylosing spondylitis - Results after 3 years
    Baraliakos, X
    Brandt, J
    Listing, J
    Rudwaleit, M
    Sieper, J
    Braun, J
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 412 - 412
  • [38] Efficacy and safety of anti-TNF therapy for ankylosing spondylitis: long-term results
    Nature Clinical Practice Rheumatology, 2008, 4 (7): : 334 - 334
  • [39] Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS)
    Revicki, Dennis A.
    Luo, Michelle P.
    Wordsworth, Paul
    Wong, Robert L.
    Chen, Naijun
    Davis, John C., Jr.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (07) : 1346 - 1353
  • [40] SHORT-TERM RESPONSE PREDICTS LONG-TERM OUTCOME AND DISCONTINUATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TNF BLOCKERS
    Baraliakos, X.
    Listing, J.
    Fritz, C.
    Sieper, J.
    Braun, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 617 - 617
12345